Assuntos
Antituberculosos , Cegueira , Tuberculose Latente , Prednisona , Uveíte , Transtornos da Visão , Humanos , Masculino , Cegueira/diagnóstico , Cegueira/etiologia , Transtornos da Visão/diagnóstico , Transtornos da Visão/etiologia , Criança , Angiofluoresceinografia , Nervo Óptico/diagnóstico por imagem , Uveíte/diagnóstico , Uveíte/tratamento farmacológico , Tuberculose Latente/diagnóstico , Tuberculose Latente/tratamento farmacológico , Antituberculosos/uso terapêutico , Resultado do Tratamento , Prednisona/uso terapêuticoRESUMO
The aberrant induction of salivary/lacrimal proteins is considered to be crucial in the pathogenesis of sicca-symptoms related to primary Sjögren syndrome (SS). We report the case of an 11-year-old boy who was admitted to hospital due to recurrent bilateral parotid gland enlargement and keratoconjunctivitis, which were diagnosed as primary SS upon a combination of laboratory and instrumental tests. The proteomic analysis of the salivary peptide complex in the patient's salivary fluid near diagnosis and after 6 months of pharmacological therapy revealed quantitative and mostly qualitative differences. This observation reveals that clinical and functional changes of the salivary glands driven by non-steroidal antinflammatory drugs might be reflected in different proteomic patterns of the salivary fluid.
Assuntos
Peptídeos/análise , Proteômica , Proteínas e Peptídeos Salivares/análise , Síndrome de Sjogren/metabolismo , Estudos de Casos e Controles , Criança , Cromatografia Líquida de Alta Pressão , Humanos , Peptídeos/química , Proteínas e Peptídeos Salivares/química , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
Sexual function is an important component of cardiac patients' quality of life and subjective well being. Patients, however, are often uninformed regarding the question of resuming sexual activity after a cardiac event. Recent epidemiologic data reveal that sexual problems are widespread and adversely affect mood, well-being, and interpersonal functioning Erectile dysfunction (ED) is the most commonly recognized and treated sexual dysfunction. It affects > 30% of men 40 to 70 years of age and its prevalence in patients with cardiovascular disease is higher than in the general population. International Guidelines has faced the problem of resuming sexual activity after a cardiac event and of the eventual suitability to the use of sildenafil or other selective inhibitor of cGMP-specific phosphodiesterase type 5 (5-PDE) for the therapy of ED in these patients. The clinical judgment should be based on the integration of clinical and instrumental data, on the evaluation of the compatibility with the foreseen energetic cost of the effort connected to sexual activity and, in case of prescription of 5-PDE inhibitors, on the eventual incompatibility with the therapy undertaken (in particular with nitrates). In the review the main reference points of literature are supplied in order to have the chance of giving motivated technical advice. Finally it is extremely important to face the problem of resuming sexual activity systematically within the cardiac rehabilitation program, with educational sessions, individual or couple conversations, and with the aid of information pamphlets.